"Le Centre Oscar Lambret de Lille, situé dans la région des Hauts-de-France, est une référence nationale en cancérologie. Hôpital universitaire, il a trois missions principales: le soin, la recherche et l'enseignement. Le Centre Oscar Lambret, créé en 1955, fait partie du groupe UNICANCER, qui réunit les 18 Centres de Lutte Contre le Cancer, établissements de santé privés d’intérêt collectif (ESPIC) exclusivement dédiés aux soins, à la recherche et à l’enseignement en cancérologie, et participant au service public hospitalier avec des tarifs conventionnels, sans aucun dépassement d’honoraires. Le Centre a été certifié par la Haute Autorité de Santé en septembre 2018."

During the past decade, Centre Oscar Lambret; Senologie conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 4 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Oscar Lambret; Senologie" #1 collaborator was "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Centre Oscar Lambret; Senologie" are "Breast Cancer" (4 trials), "Advanced Breast Cancer" (1 trials), "Chemotherapy-Induced Peripheral Neuropathy" (1 trials), "Metastatic Breast Cancer" (1 trials) and "Triple-Negative Breast Cancer" (1 trials). Many other conditions were trialed in "Centre Oscar Lambret; Senologie" in a lesser frequency.

Most popular intervention types in "Centre Oscar Lambret; Senologie" are "Drug" (7 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Trastuzumab Emtansine" (2 trials), "Atezolizumab" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody" (1 trials) and "Atezolizumab Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre Oscar Lambret; Senologie" are 6 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Centre Oscar Lambret; Senologie". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Centre Oscar Lambret; Senologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centre Oscar Lambret; Senologie, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".